The Clinical and Economic Impact of Genotype Testing at First-line Antiretroviral Therapy Failure for HIV-Infected Patients in South Africa | Zendy

Julie H. Levison | Zendy; Robin Wood | Zendy; Catherine Scott | Zendy; Andrea Ciaranello | Zendy; Neil Martinson | Zendy; Corina Rusu | Zendy; Elena Losina | Zendy; Kenneth A. Freedberg | Zendy; Rochelle P. Walensky | Zendy

Open Access

The Clinical and Economic Impact of Genotype Testing at First-line Antiretroviral Therapy Failure for HIV-Infected Patients in South Africa

Author(s) -

Julie H. Levison,

Robin Wood,

Catherine Scott,

Andrea Ciaranello,

Neil Martinson,

Corina Rusu,

Elena Losina,

Kenneth A. Freedberg,

Rochelle P. Walensky

Publication year - 2012

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cis887

Subject(s) - life expectancy , genotype , medicine , viral load , cohort , cost effectiveness , demography , human immunodeficiency virus (hiv) , virology , environmental health , biology , population , genetics , risk analysis (engineering) , sociology , gene

In resource-limited settings, genotype testing at virologic failure on first-line antiretroviral therapy (ART) may identify patients with wild-type (WT) virus. After adherence counseling, these patients may safely and effectively continue first-line ART, thereby delaying more expensive second-line ART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research